Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan
**Background:** Antimicrobial resistance (AMR) represents a significant global public health crisis. Despite ample availability of Gram-positive antibiotics, there is a distinct lack of agents against Gram-negative pathogens, including carbapenem-resistant Enterobacterales, which remains a real thre...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2021-10-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.28327 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860283538407424 |
|---|---|
| author | Tetsuya Matsumoto Oliver Darlington Ryan Miller Jason Gordon Phil McEwan Takahisa Ohashi Amer Taie Akira Yuasa |
| author_facet | Tetsuya Matsumoto Oliver Darlington Ryan Miller Jason Gordon Phil McEwan Takahisa Ohashi Amer Taie Akira Yuasa |
| author_sort | Tetsuya Matsumoto |
| collection | DOAJ |
| description | **Background:** Antimicrobial resistance (AMR) represents a significant global public health crisis. Despite ample availability of Gram-positive antibiotics, there is a distinct lack of agents against Gram-negative pathogens, including carbapenem-resistant Enterobacterales, which remains a real threat in Japan. The AMR Action Plans aim to mitigate the growing public health concern posed by AMR.
**Objective:** This study aims to estimate the clinical and economic outcomes of drug-resistant Gram-negative pathogens forecasts for Japan to guide resource allocation defined within the upcoming National AMR Action Plan.
**Methods:** A previously published and validated dynamic health economic model was adapted to the Japanese setting. The model used a 10-year time horizon with a willingness-to-pay threshold of ¥5 000 000 (US $46 827) and discounting was applied at a rate of 2% to costs and benefits. Clinical and economic outcomes were assessed as a function of varying AMR levels of three Gram-negative pathogens in Japan by up to 100% of the current level.
**Results:** Reducing drug-resistant Gram-negative pathogens in Japan has the potential to save 4 249 096 life years, corresponding to 3 602 311 quality-adjusted life years. The associated maximum clinical and economic gains were estimated at up to 4 422 284 bed days saved, up to 3 645 480 defined daily doses of antibiotics avoided, up to ¥117.6 billion (US $1.1 billion) saved in hospitalization costs, and a net monetary benefit of up to ¥18.1 trillion (US $169.8 billion).
**Discussion:** Learnings from this study can be used by the Japanese government to help inform decision-making on the strategies that may be included in the upcoming National AMR Action Plan and facilitate allocation of the required budget.
**Conclusions:** This analysis demonstrated the considerable economic and clinical value of reducing AMR levels of three Gram-negative pathogens in Japan and could be utilized to support the valuation of antimicrobial treatment and resistance in Japan and more broadly. |
| format | Article |
| id | doaj-art-5fc2e2daec5e4d05be397da8d879db69 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2021-10-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-5fc2e2daec5e4d05be397da8d879db692025-02-10T16:13:17ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362021-10-0182Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in JapanTetsuya MatsumotoOliver DarlingtonRyan MillerJason GordonPhil McEwanTakahisa OhashiAmer TaieAkira Yuasa**Background:** Antimicrobial resistance (AMR) represents a significant global public health crisis. Despite ample availability of Gram-positive antibiotics, there is a distinct lack of agents against Gram-negative pathogens, including carbapenem-resistant Enterobacterales, which remains a real threat in Japan. The AMR Action Plans aim to mitigate the growing public health concern posed by AMR. **Objective:** This study aims to estimate the clinical and economic outcomes of drug-resistant Gram-negative pathogens forecasts for Japan to guide resource allocation defined within the upcoming National AMR Action Plan. **Methods:** A previously published and validated dynamic health economic model was adapted to the Japanese setting. The model used a 10-year time horizon with a willingness-to-pay threshold of ¥5 000 000 (US $46 827) and discounting was applied at a rate of 2% to costs and benefits. Clinical and economic outcomes were assessed as a function of varying AMR levels of three Gram-negative pathogens in Japan by up to 100% of the current level. **Results:** Reducing drug-resistant Gram-negative pathogens in Japan has the potential to save 4 249 096 life years, corresponding to 3 602 311 quality-adjusted life years. The associated maximum clinical and economic gains were estimated at up to 4 422 284 bed days saved, up to 3 645 480 defined daily doses of antibiotics avoided, up to ¥117.6 billion (US $1.1 billion) saved in hospitalization costs, and a net monetary benefit of up to ¥18.1 trillion (US $169.8 billion). **Discussion:** Learnings from this study can be used by the Japanese government to help inform decision-making on the strategies that may be included in the upcoming National AMR Action Plan and facilitate allocation of the required budget. **Conclusions:** This analysis demonstrated the considerable economic and clinical value of reducing AMR levels of three Gram-negative pathogens in Japan and could be utilized to support the valuation of antimicrobial treatment and resistance in Japan and more broadly.https://doi.org/10.36469/001c.28327 |
| spellingShingle | Tetsuya Matsumoto Oliver Darlington Ryan Miller Jason Gordon Phil McEwan Takahisa Ohashi Amer Taie Akira Yuasa Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan Journal of Health Economics and Outcomes Research |
| title | Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan |
| title_full | Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan |
| title_fullStr | Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan |
| title_full_unstemmed | Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan |
| title_short | Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan |
| title_sort | estimating the economic and clinical value of reducing antimicrobial resistance to three gram negative pathogens in japan |
| url | https://doi.org/10.36469/001c.28327 |
| work_keys_str_mv | AT tetsuyamatsumoto estimatingtheeconomicandclinicalvalueofreducingantimicrobialresistancetothreegramnegativepathogensinjapan AT oliverdarlington estimatingtheeconomicandclinicalvalueofreducingantimicrobialresistancetothreegramnegativepathogensinjapan AT ryanmiller estimatingtheeconomicandclinicalvalueofreducingantimicrobialresistancetothreegramnegativepathogensinjapan AT jasongordon estimatingtheeconomicandclinicalvalueofreducingantimicrobialresistancetothreegramnegativepathogensinjapan AT philmcewan estimatingtheeconomicandclinicalvalueofreducingantimicrobialresistancetothreegramnegativepathogensinjapan AT takahisaohashi estimatingtheeconomicandclinicalvalueofreducingantimicrobialresistancetothreegramnegativepathogensinjapan AT amertaie estimatingtheeconomicandclinicalvalueofreducingantimicrobialresistancetothreegramnegativepathogensinjapan AT akirayuasa estimatingtheeconomicandclinicalvalueofreducingantimicrobialresistancetothreegramnegativepathogensinjapan |